Metraipolis › archive › dc_0da69cfd9679
Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro — Europe PMC PMID:32746451
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/32746451
- DOI
- 10.1371/journal.pone.0235676
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-07T21:57:08.315Z
- SHA-256 of the archived text
4d38faa89de61dec109a95cfe8f7f123b51bd679b7730be89f7a517817489945- Stable URL of this page
https://metraipolis.com/documento/dc_0da69cfd9679
How to cite
Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro — Europe PMC PMID:32746451 — Europe PMC (en), https://europepmc.org/article/MED/32746451 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_0da69cfd9679 (Metraipolis archive dc_0da69cfd9679, sha256 4d38faa89de61dec109a95cfe8f7f123b51bd679b7730be89f7a517817489945)
BibTeX
@misc{dc0da69cfd9679,
title = {Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro — Europe PMC PMID:32746451},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/32746451},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_0da69cfd9679; sha256 4d38faa89de61dec109a95cfe8f7f123b51bd679b7730be89f7a517817489945},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32746451. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Breast cancer is the second leading cause of death among women globally. The existing treatment options for breast cancer are largely associated with severe toxicities, and lower efficacies. Therefore, there is an urgent need for the development of non-toxic effective drugs against breast cancer. For this purpose, drug repositioning strategy was used to evaluate the anti-cancer potential of a library of heterocyclic drugs. The major advantage of drug repurposing is that the pharmacokinetic, pharmacodynamic, and toxicity profiles of drugs are well documented. In the current study, we screened 97 drugs of different chemical classes, and among them aripiprazole, an antipsychotic drug, was found to be sufficiently active against breast cancer cell line MCF-7. Aripiprazole showed a cytotoxicity (IC50 = 12.1 ± 0.40 μM) to MCF-7 cells, comparable to the standard anticancer drug doxorubicin (IC50 = 1.25 ± 0.34 μM). Aripiprazole was also found to be active against other cancer cell lines, including MDA-MB-231 (IC50 = 19.83 ± 0.27 μM), AU565 (IC50 = 18.02 ± 0.44 μM), and BT-474 (IC50 = 36.42 ± 0.12 μM). Aripiprazole significantly inhibited the cell cycle progression at subG0G1 phase, and enhanced apoptosis in MCF-7 breast cancer cells. The drug was also able to significantly increase the nuclear condensation, and modulated the expression of certain genes involved in breast cancer, such as caspases 3, and 9, BAK-1, C-MYC, BCL2L1, BCL-10, and BCL-2. Further studies are needed to explore the effect of aripiprazole on intrinsic and extrinsic pathways of apoptosis in cancer cells. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-08-03). Identificativi: PMID 32746451 · PMCID PMC7398703 · DOI 10.1371/journal.pone.0235676. Pagina: https://europepmc.org/article/MED/32746451 — https://doi.org/10.1371/journal.pone.0235676. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-07T21:53:00.837Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.